(720 ILCS 570/316)
    Sec. 316. Prescription Monitoring Program.
    (a) The Department must provide for a Prescription Monitoring Program for Schedule II, III, IV, and V controlled substances that includes the following components and requirements:
        (1) The dispenser must transmit to the central
repository, in a form and manner specified by the Department, the following information:
            (A) The recipient's name and address.
            (B) The recipient's date of birth and gender.
            (C) The national drug code number of the
controlled substance dispensed.
            (D) The date the controlled substance is
            (E) The quantity of the controlled substance
dispensed and days supply.
            (F) The dispenser's United States Drug
Enforcement Administration registration number.
            (G) The prescriber's United States Drug
Enforcement Administration registration number.
            (H) The dates the controlled substance
prescription is filled.
            (I) The payment type used to purchase the
controlled substance (i.e. Medicaid, cash, third party insurance).
            (J) The patient location code (i.e. home, nursing
home, outpatient, etc.) for the controlled substances other than those filled at a retail pharmacy.
            (K) Any additional information that may be
required by the department by administrative rule, including but not limited to information required for compliance with the criteria for electronic reporting of the American Society for Automation and Pharmacy or its successor.
        (2) The information required to be transmitted under
this Section must be transmitted not later than the end of the next business day after the date on which a controlled substance is dispensed, or at such other time as may be required by the Department by administrative rule.
        (3) A dispenser must transmit the information
required under this Section by:
            (A) an electronic device compatible with the
receiving device of the central repository;
            (B) a computer diskette;
            (C) a magnetic tape; or
            (D) a pharmacy universal claim form or Pharmacy
Inventory Control form;
        (4) The Department may impose a civil fine of up to
$100 per day for willful failure to report controlled substance dispensing to the Prescription Monitoring Program. The fine shall be calculated on no more than the number of days from the time the report was required to be made until the time the problem was resolved, and shall be payable to the Prescription Monitoring Program.
    (b) The Department, by rule, may include in the Prescription Monitoring Program certain other select drugs that are not included in Schedule II, III, IV, or V. The Prescription Monitoring Program does not apply to controlled substance prescriptions as exempted under Section 313.
    (c) The collection of data on select drugs and scheduled substances by the Prescription Monitoring Program may be used as a tool for addressing oversight requirements of long-term care institutions as set forth by Public Act 96-1372. Long-term care pharmacies shall transmit patient medication profiles to the Prescription Monitoring Program monthly or more frequently as established by administrative rule.
    (d) The Department of Human Services shall appoint a full-time Clinical Director of the Prescription Monitoring Program.
    (e) (Blank).
    (f) Within one year of the effective date of this amendatory Act of the 100th General Assembly, the Department shall adopt rules requiring all Electronic Health Records Systems to interface with the Prescription Monitoring Program application program on or before January 1, 2021 to ensure that all providers have access to specific patient records during the treatment of their patients. These rules shall also address the electronic integration of pharmacy records with the Prescription Monitoring Program to allow for faster transmission of the information required under this Section. The Department shall establish actions to be taken if a prescriber's Electronic Health Records System does not effectively interface with the Prescription Monitoring Program within the required timeline.
    (g) The Department, in consultation with the Advisory Committee, shall adopt rules allowing licensed prescribers or pharmacists who have registered to access the Prescription Monitoring Program to authorize a designee to consult the Prescription Monitoring Program on their behalf. The rules shall include reasonable parameters concerning a practitioner's authority to authorize a designee, and the eligibility of a person to be selected as a designee.
(Source: P.A. 99-480, eff. 9-9-15; 100-564, eff. 1-1-18.)